 | |
| Vaccine description | |
|---|---|
| Target | Typhoid |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Vivotif |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Ty21a is a live attenuated bacterial vaccine that protects against typhoid. First licensed in Europe in 1983 and in the United States in 1989, it is an orally administered, live-attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been deleted so as to render it harmless but nevertheless immunogenic. It is one of the three typhoid vaccines currently recommended by the World Health Organization (the other two being the Typhoid Conjugate Vaccine (TCV) and Vi capsular polysaccharide vaccine).[1]
The vaccine is given by mouth. The vaccine is presented either as enteric coated capsules or as a liquid suspension. The vaccine must be stored at 2 to 8 °C, but will retain its potency for 14 days at 25 °C.[2]
- ^ "WHO position paper on typhoid Vaccines, March 2018" (PDF). World Health Organization. March 2018. Retrieved 2019-05-05.
- ^ World Health Organization (February 2008). "Typhoid vaccines: WHO position paper" (PDF). Relevé Épidémiologique Hebdomadaire. 83 (6): 49–59. PMID 18260212.